
Machine learning can predict preeclampsia by week 34 of pregnancy
A machine-learning model developed by Weill Cornell Medicine investigators may provide clinicians with an early warning of a complication that can occur late in pregnancy.

A machine-learning model developed by Weill Cornell Medicine investigators may provide clinicians with an early warning of a complication that can occur late in pregnancy.

A team of researchers from Taiwan has developed PanMETAI, an AI-powered platform that analyzes metabolic fingerprints in a simple blood sample to detect pancreatic cancer at its earliest stages—when treatment is most effective—achieving up to 94% diagnostic accuracy.

A new tool co-developed by investigators from Cedars-Sinai Health Sciences University can predict which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free DNA (cfDNA) fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis.

TORONTO and DALLAS, March 3, 2026 /PRNewswire/ – Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (“Perimeter” or the “Company”), a commercial-stage medical technology company, announced today that it has received U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) for Claire™ (formerly the Perimeter OCT B-Series with ImgAssist AI 2.0), the first AI-enabled imaging device approved in the United States for intraoperative breast cancer margin assessment.

A new, fully customizable 3D printed socket design is set to transform the prosthetics industry.

STOCKHOLM, March 2, 2026 /PRNewswire/ — SciBase Holding AB (“SciBase”) (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that it has received approval by FDA for its supplement to extend the labelling to include other healthcare professionals and not only dermatologists to perform the Nevisense procedure

DENVER, March 2, 2026 /PRNewswire/ — Ultrasound AI, a pioneer in artificial intelligence applications for medical imaging, today announced it has received FDA De Novo clearance for its flagship Delivery Date AI technology, a cloud-based SaMD that determines a Predicted Delivery Date (PDD) solely from standard ultrasound images and seamless integration into current OB/MFM prenatal visit workflows; PDD is provided in real-time for actionable decision-making by the clinical team.

An AI can accurately diagnose a rare endocrinological condition just by analyzing pictures of the back of the hand and the clenched fist. The privacy-conscious achievement by Kobe University holds promise for establishing more efficient referral systems and reducing health care disparities across communities.

TechLive is a multimodality, vendor-agnostic remote scanning and radiology management solution extending expert oversight across multiple modalities